Buy & Sell Amgen, Inc. (AMGN) – Amgen, Inc. Price Today
Aura AI Summary
Key Stats
- $179.12BMarket Cap
- HealthSector
- -16.57%3M Drawdown
- $224.40BEnterprise Value
- 3.04%Dividend Yield
- 75 daysTypical Hold Time
Amgen, Inc. (AMGN) is currently valued at a market capitalization of $179.12B, with an enterprise value of $224.40B. Over the past 52 weeks, Amgen, Inc. has traded between a low of $262.28 and a high of $388.16, highlighting its annual price range. Over the past three months, Amgen, Inc. has recorded a drawdown of -16.57%, reflecting recent price volatility. Amgen, Inc. offers a dividend yield of 3.04%, with the most recent dividend of $2.52 paid on 13 Feb 26. On average, investors hold Amgen, Inc. for approximately 75 days, indicating typical investor behavior on the platform.
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Most Recent News
Gaia, Inc. faces fraud investigation after missing Q1 revenue estimates and stock drop.
The Schall Law Firm is investigating Gaia, Inc. for potential securities law violations following the company's Q1 2026 financial results announcement. Gaia missed revenue estimates, and its CEO cited strategic changes expected to slow near-term reve...
76% of firms appoint chief AI officers amid AI-driven shifts in workforce and leadership roles
A recent IBM report reveals that 76% of surveyed companies have created the role of chief AI officer (CAIO) to lead AI transformations, up significantly from 26% in 2025. This shift reflects AI's growing impact on corporate strategy and workforce dyn...
Golub Capital BDC holds steady despite rising credit stress and portfolio challenges.
Golub Capital BDC remains a Hold as its portfolio quality shows signs of deterioration, with nonaccrual loans rising to 1.4% and payment-in-kind (PIK) income increasing to 9%, indicating some credit stress. The fund’s software sector exposure is most...